AUTHORS
Noushin Farnoud, PhD, MASc, Erin McGovern, BA2, Amritha Varshini Varshini Hanasoge Hanasoge Somasundara, PhD3, Sarun Sereewattanawoot, MD, PhD4, Christopher Famulare, MS5, Jesús Gutiérrez-Abril, PhD6, Bridget Kelly Marcellino, MD, PhD7, Eliyahu Havasov8, Christina Bravo Neary9, Michael Mauro, MD10, Brian Chernak, MD11, Tamanna Haque, MD12, Francesco Maura, MD13, Amylou C Dueck, PhD14, Andrew McPherson, PhD15, John O. Mascarenhas, MD16, Ross L. Levine, Prof. Dr.17, Ronald Hoffman, MD18, Raajit K. Rampal, MD, PhD19
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
2 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
3 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
4 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
5 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
6 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, United States
8 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
9 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
10 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
11 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
12 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
13 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
14 Mayo Clinic, Phoenix, United States
15 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
16 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States
17 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
18 Icahn School of Medicine at Mount Sinai, New York, United States
19 Memorial Sloan Kettering Cancer Instutute, New York, New York, United States
ABSTRACT
Background
RAS-pathway mutations, including CBL (11q23.3), are associated with adverse outcomes in MPNs and resistance to JAK inhibition, but the clinical significance of CBL clonal expansion across MPN disease phases is poorly defined. We evaluated CBL variant allele fraction (VAF), longitudinal dynamics, and compound mutations (≥2 concurrent variants) across chronic and transformed MPN.
Methods
We retrospectively screened 1,569 samples in the Memorial Sloan Kettering and MPN Research Consortium sequencing repository (973 chronic-phase MPN, 427 PMF, 169 accelerated/blast-phase MPN). Among these, we identified 73 oncogenic or likely oncogenic CBL variants (36 chronic-phase, 26 PMF, 11 accelerated/blast-phase) across 59 samples from 46 patients. VAF was compared across these groups (Kruskal-Wallis, with pairwise Mann-Whitney U comparisons), within-patient VAF trajectories were examined for patients with serial sampling (22/46, 48% of CBL-mutated cases), and the frequency of compound CBL mutations per sample was quantified. Cases with multiple CBL variants underwent copy-number and read-backed phasing analysis where feasible.
Results
CBL alterations showed a clear phase-dependent increase in both prevalence and clonal dominance. Mutation prevalence rose from 3.1% in chronic-phase MPN to 4.7% in PMF and 5.3% in accelerated/blast-phase disease. Median CBL VAF increased stepwise from 7% in chronic-phase (n=36), to 12.8% in PMF (n=26), and 26% in transformed MPN (n=11; Kruskal-Wallis p<0.05). When chronic-phase and PMF cases were combined, CBL VAF was significantly higher in transformed disease (26% vs 8.4%; n=11 vs 62; Mann-Whitney p=7.9×10⁻³). Pairwise comparisons localized the major increase to transformation: CBL VAF was significantly higher in transformed disease than in either PMF (p=3.3×10⁻²) or chronic-phase non-PMF MPN (p=5.8×10⁻³), whereas the more modest increase from chronic-phase MPN to PMF was not significant. Together, these findings support gradual CBL clonal expansion during chronic disease evolution followed by a sharp increase in clonal dominance at transformation.
Across the cohort, mutations clustered within the canonical RING/linker region of CBL (aa 366-420), consistent with the established CBL mutational landscape in myeloid neoplasms. CBL mutations were significantly enriched with ASXL1 alterations (18/46 CBL-mutant patients; OR=4.4, FDR=4.4×10⁻⁴), as well as NRAS and EZH2 mutations (8/46 each; OR=6.7, FDR=3.6×10⁻³). This links CBL to both RAS-pathway activation (associated with JAK-inhibitor resistance) and high-risk epigenetic lesions that may cooperate in clonal evolution.
Longitudinal and clonal-architecture analyses further showed CBL can directly participate in progression. In one illustrative paired case, a CBL mutation expanded from a minor subclone at chronic-phase MPN (3% VAF) to biallelic dominance at progression to MPN-AP/BP (87% VAF), accompanied by a co-occurring −11q deletion. Compound CBL mutations were also unexpectedly frequent, occurring in 11/59 samples (18.6%). One patient carried three concurrent CBL variants arising from a shared ancestral JAK2/IDH2-mutant clone and reflecting convergent evolution through two independent mechanisms: a dominant, near-clonal CBL branch rendered biallelic by 11q copy-neutral LOH, and a separate minor branch containing two additional CBL variants in trans. Notably, this patient achieved only stable disease with combined JAK/IDH2-inhibitor therapy, with no meaningful reduction in the JAK2/IDH2-mutant clonal burden, unlike the CR/CRi responses in the same trial in patients without CBL involvement. Collectively, these findings position CBL not merely as a recurrent lesion, but as a transformation-associated driver of clonal expansion and convergent evolution that also contributes to therapeutic resistance in advanced MPN.
Conclusions
Our results showed that expansion of CBL-mutant clones distinguished transformed from chronic-phase MPN, with frequent compound mutations revealing convergent chromosomal and mutational routes to CBL pathway disruption in the setting of therapy. These findings support CBL clonal burden and allelic configuration as candidate biomarkers of high-risk clonal evolution and potential markers of treatment resistance. Single-cell whole-genome sequencing (DLP+) is underway to resolve CBL clonal architecture and reconstruct evolutionary trajectories across MPN disease states.
DISCLOSURES
Noushin Farnoud, PhD, MASc: No relevant conflicts of interest to declare.